EGFR and hepatocellular carcinoma: Since the activation of the EGFR/PI3K/AKT/mTOR signaling pathway significantly contributes to HCC development, various inhibitors of this signaling pathway have been administered to murine models of HCC to investigate their effects on HCC in vivo (Table 3).